Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Medifast, a health and wellness company, has seen its stock price decline by 76% since 2021, despite its Optavia platform helping over 2 million customers with weight loss. The company's earning power value (EPV) and adjusted asset value (AV) suggest the stock is undervalued, with potential for significant returns for value-oriented investors. However, risks include competitive entry, potential malinvestment, MLM regulations and prejudice, and health and sustainability concerns around Medifast's products.

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Benchmark Electronics

Cross Country Healthcare

Crescent Energy

Vivid Seats

Titan

Select Energy Services

Small-cap breakout stocks offer plenty of robust upside opportunities, but only for the patient and the adventurous. As with practically anything in life, the greater the reward, the higher the risk.

7 Small-Cap Stocks Signaling a Sizeable Breakout

Artisan Partners Asset Management

Cogent Communications Holdings

CTO Realty Growth

Enbridge

Hess Midstream Partners

Innovative Industrial Properties

International Paper

Kinder Morgan

Moelis

Altria

ONEOK

OneMain Hld

Alpine Income Property Trust

TC Energy

Williams

Dividend growth stocks can provide growing wealth over time to income investors and potentially promote share price appreciation. The article explores five dividend growth stocks for June: OneMain Holdings, Enbridge, Alpine Income Property Trust, TC Energy Corp, and Cogent Communications Holdings Inc. These stocks were screened based on dividend safety, dividend growth, and dividend consistency, with more due diligence needed before making an investment decision.

June's 5 Dividend Growth Stocks With 5.93%+ Yields

I view Medifast's traditional business model at increasing risk from the growing popularity of GLP-1-based drugs. Recent M&A activity within the industry provides an indication of the premium investors are willing to pay for those who embrace change. Medifast is currently deploying positive cash flow dollars to the maintenance of an over 8% yielding dividend as well as to share repurchases.

Medifast: A Revamp Is Necessary, An Embrace Of GLP-1s Can Help

Medifast ( MED , Financial) is a mission-driven company supporting health and well-being, helping its customers transform their lives by providing healthy living products and programs. The company has developed the OPTAVIA brand that offers healthy products and support from experts in science, health and wellness so that customers achieve a transformation in their lives focusing on healthy habits over time.

Medifast: A High Dividend Yield and Cheap Valuation

CompX International

Taitron Components

Crown Crafts

Evolution Petroleum

Epsilon Energy Ltd

In arguably a vast majority of cases, the concept of top safe high-yield dividend stocks represents an oxymoron. Stated differently, if you want robust passive income, you usually must concede your preferences for reliability and sustainability.

7 Safe High-Yield Dividend Stocks to Buy in June 2023

Medifast is a leader in the weight loss industry with a growing customer base. However, Medifast's stock price has gradually declined in 2023.

Medifast Holds Value During Headwinds

Agree Realty

National Retail Properties

Starbucks

Verizon

Invest in high-quality stocks for the long term/mostly investment grade companies. The goal of this portfolio is to collect weekly dividend checks that cover my monthly expenses in retirement.

The Dividend Collectuh's 18 Stock Tim Duncan Portfolio

May started off on a bit of a sour note, with the broader indexes giving up some of their gains. Declining prices have helped push up dividend yields across the board as share prices fall.

May's 5 Dividend Growth Stocks With 6.08%+ Yields

Medifast's Q1 2023 EPS of $3.67 beats by $1.27 and revenue of $349M beats analysts' expectations by $29.5M. For Q2 2023, the company expects a ~25% decline in revenue and a ~50% decline in EPS.

Medifast: Strong Earnings But Guidance Disappoints

Medifast's (MED) first-quarter 2023 results reflect lower sales on reduced Coach productivity and cost inflation. While earnings increase year over year.

Medifast's (MED) Q1 Earnings Top Estimates, Sales Decline Y/Y

Medifast, Inc. (NYSE:MED ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Steve Zenker - Vice President of Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Linda Bolton-Weiser - D.A. Davidson Operator Good afternoon, and welcome to the Medifast First Quarter 2023 Earnings Conference Call.

Medifast, Inc. (MED) Q1 2023 Earnings Call Transcript

BALTIMORE , May 1, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities,  OPTA VIA®, today reported results for the first quarter ended March 31, 2023. First Quarter 2023 Revenue of $349.0 million, with revenue per active earning coach of $5,945 Independent active earning OPTAVIA Coaches of 58,700 Net income of $40.0 million Earnings per diluted share ("EPS") of $3.67 Cash and cash equivalents of $123.7 million and no interest bearing debt "We're pleased to see revenue and operating income both ahead of expectations in the quarter, as we continue to adjust to the changing dynamics of the business environment," said Dan Chard, Medifast's Chairman & Chief Executive Officer.

Medifast Announces First Quarter 2023 Financial Results

Medifast's (MED) first-quarter performance is likely to reflect the adverse impacts of macroeconomic volatility and increased inflation.

Factors to Consider Ahead of Medifast's (MED) Q1 Earnings

Apollo Global Management

Blackstone Group

Lazard

RMR Group

TravelCenters of America

Western Union

April's 5 Dividend Growth Stocks With 6.30%+ Yields

Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the first quarter ended March 31, 2023 on Monday, May 1, 2023, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.

Medifast to Announce Financial Results for the First Quarter Ended March 31, 2023

Medifast stock was truly exceptional, as it embodied the desirable traits of value, growth, and dividend stocks all in one. However, latest quarterly earnings were down around 10% YoY.

Medifast: Looking Attractively Valued Even Amidst Declining Fundamentals

Apple

Armada Hoffler Properties

Algonquin Power & Utilities

Avient Corp

Booz Allen Hamilton Hld

Brookfield Renewable Partners

Bar Harbor Bankshares

Conagra Brands

Crown Castle International

EastGroup Properties

Enterprise Products Partners

EPR Properties

Essential Properties Realty Trust Inc

Alphabet

Intel

Leggett & Platt

Mid-America Apartment Communities

Medtronic

Dividend Growth Investing Like Peter Lynch

Company Recognized as One of the Top 500 Companies with the Highest Compound Annual Revenue Growth Between 2018 and 2021 BALTIMORE , April 3, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA®, today announced that it has been ranked by Financial Times as one of The Americas' Fastest Growing Companies based on compound annual growth in revenues from 2018 to 2021. "Medifast has been a leader in the health and wellness industry for more than 40 years, during which time our simple yet comprehensive approach has resonated with more than two million people," said Dan Chard, Chairman and CEO of Medifast.

Medifast Named to Financial Times' List of The Americas' Fastest Growing Companies

The latest dividend yields over 6% on its market price. The latest dividend payout is less than 50% of its latest quarter earnings.

Medifast: A High Yield But Low Portfolio Size Hold For Me

Medifast operates in the health and wellness industry and is the owner of the OPTAVIA brand, a popular weight loss and diet program. The company generates its sales through a large network of independent coaches who work at arms-length with its customer base.

Medifast: An Attractive Dividend But Operating Results Need Further Improvement

Healthcare Services Group

Janus Henderson Group

After a strong start to the year, February pulled us back down to reality. Asset prices have again dropped due to expectations of higher interest rates for longer.

March's 5 Dividend Growth Stocks With 5.73%+ Yields

BALTIMORE , March 2, 2023 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTA VIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr.

Medifast Appoints Steven Zenker as Vice President of Investor Relations

Medifast's (MED) fourth-quarter 2022 results reflect reduced Coach productivity and cost inflation. While earnings increase year over year, revenues dip

Medifast (MED) Stock Down Despite Q4 Earnings, Sales Beat

Medifast (MED) delivered earnings and revenue surprises of 69.72% and 9.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Tops Q4 Earnings and Revenue Estimates

News for Medifast Stock (MED)